Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2020 / Cilt: 25 - Sayı: 3

Distribution and Prevalence of High-Risk Human Papillomavirus Genotypes in Cervical Specimens

Servikal Örneklerde Yüksek Riskli Human Papillomavirüs Genotiplerinin Dağılımı ve Prevalansı

Pages
325–331
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

HPV type 16 is seen with a high rate in our region.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Human papillomavirus (HPV) is frequently a sexually transmitted virus and can cause cervical cancer in women.
📊
Key Findings & Data:Materials and Methods: Between 1 July, 2017 and 1 March, 2019, 433 cervical swabs were sent to Ataturk University, Medical Faculty Hospital, Medical Microbiology Laboratory due to suspicion of HPV.
💡
Conclusion & Impact:HPV type 16 is seen with a high rate in our region.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Human papillomavirus (HPV) is frequently a sexually transmitted virus and can cause cervical cancer in women. Cervical cancer is the second most common type of cancer among the developing countries. In this study, cervical HPV DNA positivity and genotype distributions were investigated in female patients living in our region and the results were compared with different studies. Materials and Methods: Between 1 July, 2017 and 1 March, 2019, 433 cervical swabs were sent to Ataturk University, Medical Faculty Hospital, Medical Microbiology Laboratory due to suspicion of HPV. Swab samples were evaluated for HPV virus using molecular (Polymerase Chain Reaction-PCR) methods. For this purpose, Xpert HPV Test (Cepheid, Inc, Sunnyvale, CA) was used to identify HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 t in a single sample. Results: Mean age of the patients ranged from 20 to 69 years, with a mean of 39.8 years (± 10.0). Positivity was detected in 62 of the 433 patients. Mean age of the positive patients was 40.2 years (± 11.3). When the positive patients were examined in terms of HPV types, the presence of HPV 16 was observed with a rate of 25.6%, while the HPV 18/45 types were found to be 9.0% in total. When patients were evaluated according to age groups, HPV DNA positivity was highest in the 25-34 age group with 38.7%. In our statistical study, there was no significant difference in HPV DNA positivity rate between the ages of 35 and under 35 years. Conclusion: This study demonstrates the prevalence and viral genotype distribution of HPV infection in women in Erzurum region. HPV type 16 is seen with a high rate in our region.

Özet

Giriş: Human papillomavirus (HPV) sıklıkla cinsel yolla bulaşabilen bir virüs olup kadınlarda servikal kansere yol açabilmektedir. Servikskanseri gelişmekte olan ülke kadınları arasında en sık görülen ikinci kanser türüdür. Bu çalışmada bölgemizde yaşayan kadınlardakiservikal HPV DNA pozitifliği ve genotip dağılımları araştırılmış olup sonuçlar farklı çalışmalar ile karşılaştırılmıştır.Materyal ve Metod: Bu çalışmada 1 Temmuz 2017 ile 1 Mart 2019 tarihleri arasında Atatürk Üniversitesi Tıp Fakültesi Hastanesi TıbbiMikrobiyoloji Laboratuvarına HPV şüphesi ile gönderilen 433 servikal sürüntü örneği incelendi. Sürüntü örnekleri moleküler (PolimerazZincir Reaksiyonu-PZR) yöntemler kullanılarak HPV virüsü açısından değerlendirildi. Bu amaçla tek örnekte HPV 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 66 ve 68 tiplerini saptayabilen Xpert HPV Test (Cepheid, Inc, Sunnyvale, CA) kitleri kullanıldı.Bulgular: Hastaların yaşları 20 ila 69 arasında olup, ortalaması 39.8 (± 10.0) idi. Toplam 433 hastanın 62’sinde (%14.3) pozitifliktespit edildi. Pozitif olan hastaların yaş ortalamaları 40.2 (± 11.3) idi. Pozitif hastalar HPV tipleri açısından incelendiğinde HPV 16varlığı %25.6 oranında görülürken, HPV 18/45 tipleri toplamda %9.0 olarak tespit edilmiştir. Hastalar yaş gruplarına göre değerlendirildiğinde HPV DNA pozitifliği en fazla %38.7 ile 25-34 yaş grubunda görülmüştür. Yaptığımız istatistiksel çalışmada 35 yaş altı ile 35yaş ve üstü hasta grupları arasında HPV DNA pozitiflik oranı açısından anlamlı bir fark görülmemiştir.Sonuç: Bu çalışma Erzurum bölgesindeki kadınlarda HPV infeksiyonunun prevalansını ve viral genotip dağılımını ortaya koymaktadır.Bölgemizde HPV 16 tipi yüksek oranda görülmektedir

🔖

Cite This Article

ÖZMEN, E., ALTOPARLAK, Ü., UYANIK, M. H., GÜLEN, A. (2020). Distribution and Prevalence of High-Risk Human Papillomavirus Genotypes in Cervical Specimens. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 25 - Sayı: 3, 325–331. https://ajindex.com/articles/348077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Avcı GA. İnsan Papillomavirusunun Genomik Yapısı ve Proteinleri. Mikrobiyol Bul 2012;46:507-15
  2. Rahman S, Pierce Campbell CM, Rollison DE, Wang W, Waterboer T, Michel A, et al. Seroprevalence and associated factors of 9-valent human Papillomavirus (HPV) types among men in the multinational HIM study. PLoS ONE 2016;11:e0167173
  3. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006;2006 Suppl:40470 4. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012;30(Suppl 5):F24-33
  4. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009 1;4:8 6. Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 2006;106:S2-S8 7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9
  5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
  6. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):F12-23
  7. Sahiner F, Gümral R, Sener K, Yiğit N, Dede M, Yapar M, et al. Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR. Mikrobiyol Bul 2012;46:624-36
  8. Leto MD, Santos Junior GF, Porro AM, Tomimori J. Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations. An Bras Dermatol 2011;86:306-17
  9. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl 5):F88-99
  10. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32
  11. Açikgöz A, Ergör G. Cervical cancer risk levels in Turkey and complianc to the national cervical cancer screening standard. Asian Pac J Cancer Prev 2011;12:923-7
  12. Altun Z, Y